Apogee Therapeutics's long-term debt is $4.9M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (March 2026), APGE shows a long-term debt of $4.9M. That compares with $7.8M in the prior-year period — down 37.4% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, APGE's long-term debt is now $4.9M (was $7.8M) — a 37.4% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Apogee Therapeutics is outperforming or lagging.
Tracking APGE's long-term debt over time shows whether Apogee Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $4.9M That compares with $7.8M in the prior-year period — down 37.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this long-term debt page, Stockcircle has Apogee Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $4.9M) with ownership activity and broader fundamentals.